JP2020510056A - 遺伝子工学菌vnp20009−mの悪性肉腫予防・治療薬の製造にお ける応用 - Google Patents
遺伝子工学菌vnp20009−mの悪性肉腫予防・治療薬の製造にお ける応用 Download PDFInfo
- Publication number
- JP2020510056A JP2020510056A JP2019550212A JP2019550212A JP2020510056A JP 2020510056 A JP2020510056 A JP 2020510056A JP 2019550212 A JP2019550212 A JP 2019550212A JP 2019550212 A JP2019550212 A JP 2019550212A JP 2020510056 A JP2020510056 A JP 2020510056A
- Authority
- JP
- Japan
- Prior art keywords
- sarcoma
- vnp20009
- application according
- genetically engineered
- methioninase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
- 遺伝子工学菌VNP20009−Mの悪性肉腫予防・治療薬の製造における応用。
- 前記肉腫は、結合組織や筋肉等の間葉組織に由来する悪性肉腫であることを特徴とする請求項1に記載の応用。
- 前記肉腫は、脂肪、筋膜、筋肉、繊維、リンパ及び血管、骨膜及び長骨の両端に生じる肉腫を含むことを特徴とする請求項2に記載の応用。
- 前記肉腫は、軟部組織肉腫及び骨肉腫を含むことを特徴とする請求項3に記載の応用。
前記遺伝子工学菌VNP20009−Mの予防・治療薬の製造における応用を開示する。 - 前記肉腫は、原発性肉腫、術後再発肉腫及び術後他の部位へ転移した肉腫を含むことを特徴とする請求項1−4のいずれか1項に記載の応用。
- 前記肉腫は、悪性肉腫の術後、肺へ転移した肉腫であることを特徴とする請求項5に記載の応用。
- 前記遺伝子工学菌VNP20009−Mの最小有効投与量は、6.4×107CFU/M2であることを特徴とする請求項1−6のいずれか1項に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子がクローニングされた弱毒ネズミチフス菌VNP20009であることを特徴とする請求項1−7のいずれか1項に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子がクローニングされたプラスミドを有する弱毒ネズミチフス菌VNP20009であることを特徴とする請求項8に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子をプラスミドにサブクローニングして、L−メチオニナーゼ発現プラスミドを得て、L−メチオニナーゼ発現プラスミドを弱毒ネズミチフス菌VNP20009に電気的形質転換する方法によって構築されることを特徴とする請求項8−9のいずれか1項に記載の応用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710216811.9A CN107115533A (zh) | 2017-04-01 | 2017-04-01 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
CN201710216811.9 | 2017-04-01 | ||
PCT/CN2018/081116 WO2018177375A1 (zh) | 2017-04-01 | 2018-03-29 | 基因工程菌vnp20009-m在制备治疗恶性肉瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510056A true JP2020510056A (ja) | 2020-04-02 |
JP6917077B2 JP6917077B2 (ja) | 2021-08-11 |
Family
ID=59726224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019550212A Active JP6917077B2 (ja) | 2017-04-01 | 2018-03-29 | 遺伝子工学菌vnp20009−mの悪性肉腫予防・治療薬の製造にお ける応用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11324781B2 (ja) |
EP (1) | EP3583956A4 (ja) |
JP (1) | JP6917077B2 (ja) |
KR (2) | KR102344837B1 (ja) |
CN (1) | CN107115533A (ja) |
AU (1) | AU2018241657B2 (ja) |
CA (1) | CA3056296C (ja) |
WO (1) | WO2018177375A1 (ja) |
ZA (1) | ZA201906176B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107115533A (zh) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150376593A1 (en) * | 2013-02-28 | 2015-12-31 | Nanjing Sinogen Biotech & Pharmaceutical Inc. | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof |
WO2016145974A1 (zh) * | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
WO2017036302A1 (zh) * | 2015-08-31 | 2017-03-09 | 南京华贞生物医药科技有限公司 | 减毒鼠伤寒沙门氏菌基因工程菌在制备治疗肝癌药物上的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT668933E (pt) * | 1992-11-19 | 2003-02-28 | Anticancer Inc | Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina |
JP2004500042A (ja) * | 1999-10-04 | 2004-01-08 | ヴァイオン ファーマシューティカルズ、インコーポレーテッド | エフェクター分子の腫瘍標的送達のための組成物および方法 |
US20030129262A1 (en) * | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
US9127284B2 (en) * | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
KR102244750B1 (ko) * | 2013-08-29 | 2021-04-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 치료적 목적을 위한 조작된 영장류 l-메티오니나제 |
CN103656684B (zh) * | 2013-12-03 | 2016-02-24 | 南京华贞生物医药科技有限公司 | 减毒鼠伤寒沙门氏菌及其基因工程菌在制备治疗胰腺癌的药物上的应用 |
CN103961721B (zh) * | 2014-04-30 | 2018-10-23 | 广州华津医药科技有限公司 | 减毒鼠伤寒沙门氏菌及其基因工程菌在制备治疗前列腺癌的药物上的应用 |
CN105802899B (zh) * | 2016-03-15 | 2022-08-02 | 中国药科大学 | 一种抑制肿瘤生长的基因工程菌及其构建方法和应用 |
CN107115533A (zh) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
-
2017
- 2017-04-01 CN CN201710216811.9A patent/CN107115533A/zh active Pending
-
2018
- 2018-03-29 AU AU2018241657A patent/AU2018241657B2/en active Active
- 2018-03-29 US US16/497,825 patent/US11324781B2/en active Active
- 2018-03-29 KR KR1020197032492A patent/KR102344837B1/ko active IP Right Grant
- 2018-03-29 CA CA3056296A patent/CA3056296C/en active Active
- 2018-03-29 KR KR1020217042303A patent/KR20210158434A/ko not_active Application Discontinuation
- 2018-03-29 EP EP18777971.5A patent/EP3583956A4/en active Pending
- 2018-03-29 WO PCT/CN2018/081116 patent/WO2018177375A1/zh unknown
- 2018-03-29 JP JP2019550212A patent/JP6917077B2/ja active Active
-
2019
- 2019-09-18 ZA ZA2019/06176A patent/ZA201906176B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150376593A1 (en) * | 2013-02-28 | 2015-12-31 | Nanjing Sinogen Biotech & Pharmaceutical Inc. | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof |
WO2016145974A1 (zh) * | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
WO2017036302A1 (zh) * | 2015-08-31 | 2017-03-09 | 南京华贞生物医药科技有限公司 | 减毒鼠伤寒沙门氏菌基因工程菌在制备治疗肝癌药物上的应用 |
Non-Patent Citations (4)
Title |
---|
BREILLOUT F ET AL.: "Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet", ANTICANCER RESEARCH, vol. Vol.7, No.4B, JPN6020037847, 1987, pages 861 - 867, ISSN: 0004420597 * |
BREILLOUT F ET AL.: "Methionine dependency of malignant tumors: a possible approach for therapy", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 82, no. 20, JPN6020037849, 1990, pages 1628 - 1632, XP001038180, ISSN: 0004420598, DOI: 10.1093/jnci/82.20.1628 * |
GUO H ET AL.: "Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo", CANCER RESEARCH, vol. 53, no. 23, JPN6020037846, 1993, pages 5676 - 5679, ISSN: 0004420596 * |
TAN Y ET AL.: "Anticancer efficacy of methioninase in vivo", ANTICANCER RESEARCH, vol. Vol.16, No.6C, JPN6020037848, 1996, pages 3931 - 3936, ISSN: 0004420599 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210158434A (ko) | 2021-12-30 |
CA3056296A1 (en) | 2018-10-04 |
US20200023020A1 (en) | 2020-01-23 |
AU2018241657A1 (en) | 2019-10-03 |
JP6917077B2 (ja) | 2021-08-11 |
US11324781B2 (en) | 2022-05-10 |
EP3583956A4 (en) | 2020-02-12 |
KR102344837B1 (ko) | 2021-12-28 |
EP3583956A1 (en) | 2019-12-25 |
KR20200013642A (ko) | 2020-02-07 |
WO2018177375A1 (zh) | 2018-10-04 |
CA3056296C (en) | 2023-01-17 |
CN107115533A (zh) | 2017-09-01 |
ZA201906176B (en) | 2021-02-24 |
AU2018241657B2 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Venot et al. | Targeted therapy in patients with PIK3CA-related overgrowth syndrome | |
CA2979760C (en) | Use of genetically engineered strain vnp20009-m in manufacturing medicaments for preventing or treating cancer metastasis | |
US11318172B2 (en) | Use of genetically engineered bacterium of attenuated Salmonella typhimurium in for treating liver cancer | |
US9816083B2 (en) | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof | |
JP2020509093A (ja) | 遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 | |
Feng et al. | Dietary nitrate supplementation prevents radiotherapy-induced xerostomia | |
JP2020510056A (ja) | 遺伝子工学菌vnp20009−mの悪性肉腫予防・治療薬の製造にお ける応用 | |
CN103330940B (zh) | 联合制剂及其在制备非小细胞肺癌药物中的应用 | |
Mengxue et al. | Clinical manifestations and molecular biology of one case of Carney complex: a case report | |
Zhang et al. | Study on the mechanism of Haizao Yuhu Decoction in inhibiting proliferation of thyroid papillary carcinoma. | |
Liu et al. | Heat shock protein 90 and prolyl hydroxylase 2 co-regulate hypoxia-inducible factor-1α expression in porcine small intestinal epithelial cells under heat stress | |
CN104173346B (zh) | 一种含阿魏酸钠的组合物 | |
Косых | Myopathy GNE: Ways to Resolve Conflict | |
Jurasunas | A Case Where Immunomodularity Food and Antioxidant Therapy was Effective in a Case of Advanced Prostate Cancer. | |
da Misericórdia | A case where immunomodularity food and antioxidant therapy was effective in a case of advanced prostate cancer. | |
Beck | Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) | |
Schmidt et al. | Regulatory Light Chain Phosphorylation Mimic S15D Causes Partial Rescue of Isometric Force Production in FHC Causing Mutation D166V | |
Book | Can fasting or calorie restriction help my body fight cancer? Could it also help cancer treatment be more effective? by admin| Mar 3, 2020| Uncategorized |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190912 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210413 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210413 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210603 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210608 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210629 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210712 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6917077 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |